The population impact of screening for Down syndrome: Audit of 19326 invasive diagnostic tests in England and Wales in 2008

Prenatal Diagnosis

Volumn 32, Issue 6, 2012, Pages 596-601

  Morris, Joan K ^a   Waters, Jonathan J ^b   de Souza, E ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMNIOCENTESIS; AMNION FLUID; ARTICLE; CHORION VILLUS SAMPLING; CHROMOSOME ANALYSIS; DIAGNOSTIC TEST; DOWN SYNDROME; ECHOGRAPHY; EDWARDS SYNDROME; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PATAU SYNDROME; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; SECOND TRIMESTER PREGNANCY; SPONTANEOUS ABORTION; UNITED KINGDOM;

ABORTION, SPONTANEOUS; ADULT; AMNIOCENTESIS; CHORIONIC VILLI SAMPLING; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 13; DOWN SYNDROME; ENGLAND; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; GESTATIONAL AGE; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS; TRISOMY; ULTRASONOGRAPHY, PRENATAL; WALES;

EID: 84861482109     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.3866     Document Type: Article

References (15)

1. Tabor A, Vestergaard HF, Lidegaard O. Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynaecol 2009;34:19-24.
2. Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villus sampling: a systematic review. Obstet Gynecol 2007;110:687-94.
3. Tabor A, Madsen M, Obel E, et al. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986;1:1287-93.
4. Morris JK, Savva GM. The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. Am J Med Genet A 2008;146A(7):827-32.
5. Savva GM, Morris JK, Mutton DE, et al. Maternal age-specific fetal loss rates in Down syndrome pregnancies. Prenat Diagn 2006;26(6):499-504.
6. Morris JK, Mutton DE, Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 2002;9(1):2-6.
7. Savva GM, Morris JK, Walker K. The maternal age specific prevalence of trisomy 13 and trisomy 18. Prenat Diagn 2010;30(1):57-64.
8. Wald NJ, Bestwick JP, Huttly WJ, et al. Validation plots in antenatal screening for Down's syndrome. J Med Screen 2006;13(4):166-71.
9. NDSCR annual report. 2009. [accessed on 22 June 2011].
10. Birth statistics. Series FM1 No.37. ONS 2010.
11. Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56-104.
12. Ball RH, Caughey AB, Malone FD, et al. First- and second-trimester evaluation of risk for Down syndrome. First and Second Trimester Evaluation of Risk (FASTER) Research Consortium. Obstet Gynecol 2007;110:10-7.
13. Johnson JP, Streets K, FitzGerald JM, et al. Influence of triple marker screen risk versus a priori risk in decision for amniocentesis by women of advanced maternal age. Prenat Diagn 1998;18:979-80.
14. Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. AJOG 2011;204:205.e1-11.
15. Chiu RWK, Akolekar R, Zheng YWL, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: a large scale validity study. BMJ 2001;342:c7401.